Press Releases
Valiltramiprosate is an investigational agent and not approved for use anywhere in the world. Statements in news stories may be aspirational.
Alzheon Partners with Czech Institute of Organic Chemistry and Biochemistry to Develop First Alzheimer’s Diagnostic Assay for Measuring Neurotoxic Beta Amyloid Oligomers in Human Brain
Assay Builds on Alzheon’s Research to Detect and Quantify Soluble Oligomers, and Enhances Phase 2 and Phase 3 Alzheimer’s Studies with Oral ALZ-801.
Alzheon to Present at H.C. Wainwright Global Life Sciences Conference
Dr. Martin Tolar, CEO of Alzheon will Present an Overview of Oral Anti-amyloid ALZ-801 Phase 3 Program at the H.C. Wainwright Global Life Sciences Virtual Conference.
Alzheon CEO Presents Overview of Oral Anti-Amyloid ALZ-801 Phase 3 Program at 9th Neurodegenerative Drug Development Summit
Dr. Martin Tolar to Provide an Update on Alzheon’s ALZ-801 Phase 3 Program and Join Panel Discussion on Current Research in Alzheimer’s Disease.
Alzheon Announces New Research Showing Accelerated Hippocampus Atrophy in APOE4/4 Patients with Early Alzheimer’s Disease
Hippocampus Atrophy and Cortical Thinning Correlate with Cognitive Decline and Show Promise as Biomarkers in Alzheimer’s Treatment and Prevention Clinical Trials.
Alzheon Announces Dosing of First Patient in ALZ-801 Phase 2 Biomarker Study in APOE4 Carriers with Early Alzheimer’s Disease
Study to Evaluate ALZ-801 Effects on Alzheimer’s Biomarkers Associated with Clinical BenefitIncludes Comprehensive Biomarker Assessment to Accelerate Development of ALZ-801 for Alzheimer’s Disease PreventionFacilitates Biomarker-Enabled Indication Expansion [...]
Alzheon Awarded $47 Million Grant from U.S. National Institute on Aging for Phase 3 Clinical Study of ALZ-801, an Oral Treatment for Alzheimer’s Disease
Study to Evaluate ALZ-801 as a Precision Medicine Approach to Early Alzheimer’s Disease in Patients with APOE4/4 Genetic ProfileGrant Supports Advancement of the First Oral Agent with [...]
Peer-Reviewed Scientific Publication Profiles First Wave of Disease-Modifying Alzheimer’s Treatments with Potential for Near Term Approval: Aducanumab, Gantenerumab, BAN2401 and ALZ-801
Anti-Amyloid Agents that Block Toxicity of Soluble Amyloid Oligomers – A Key Driver of Alzheimer’s Disease – Show Positive Clinical Effects and Consistent Biomarker ResultsSelectivity for Amyloid [...]
Alzheon Announces Appointments of Noel Dunn, Jordan Heller, and Diane Jorkasky, MD, to Board of Directors
FRAMINGHAM, Mass., January 7, 2020 – Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease (AD) and other neurodegenerative [...]
Alzheon Publication Defines New Path for 2nd Generation Anti-Amyloid Drugs for Alzheimer’s Disease, Supporting Launch of Phase 3 Study with ALZ-801 Oral Tablet
Publication in Alzheimer's & Dementia, The Journal of the Alzheimer's Association, Details Scientific Underpinnings for ALZ-801 to Slow or Stop Disease Course Publication Outlines Therapeutic Characteristics [...]
Alzheon Presents Data on the Discovery of 3-SPA, an Endogenous Substance in the Human Brain, at the Alzheimer’s Association International Conference
3-SPA, also a Product of ALZ-801, Prevents Formation of Toxic Beta Amyloid Oligomers, the Key Driver of Alzheimer’s Disease FRAMINGHAM, Mass., July 14, 2019 – Alzheon, Inc., a [...]
Newsletter
Sign up for updates
Get the latest Alzheon news in your inbox.
Not seeing the signup form? An ad or privacy blocker may be hiding it – email info@alzheon.com and we’ll add you to the list.
